Hyperandrogenemia predicts metabolic phenotype in polycystic ovary syndrome: The utility of serum androstenedione

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 3, 2014, Pages 1027-1036

  O'Reilly, Michael W ^a   Taylor, Angela E ^a   Crabtree, Nicola J ^b   Hughes, Beverly A ^a   Capper, Farfia ^b   Crowley, Rachel K ^a   Stewart, Paul M ^a,c   Tomlinson, Jeremy W ^a   Arlt, Wiebke ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROSTENEDIONE; TESTOSTERONE;

ADULT; ANDROGEN BLOOD LEVEL; ANDROGEN METABOLISM; ANDROSTENEDIONE BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE SEVERITY; DYSGLYCEMIA; FEMALE; HUMAN; HYPERANDROGENISM; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MASS FRAGMENTOGRAPHY; METABOLIC DISORDER; ORAL GLUCOSE TOLERANCE TEST; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROGNOSIS; REFERENCE VALUE; TESTOSTERONE BLOOD LEVEL;

ADULT; ANDROGENS; ANDROSTENEDIONE; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERANDROGENISM; PHENOTYPE; POLYCYSTIC OVARY SYNDROME; PREDICTIVE VALUE OF TESTS; YOUNG ADULT;

EID: 84895800357     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-3399     Document Type: Article

References (47)

1. Franks S. Polycystic ovary syndrome. N Engl J Med. 1995;333:853-861.
2. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004;89:2745-2749. (Pubitemid 38766360)
3. Fauser BC, Tarlatzis BC, Rebar RW, et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): The Amsterdam ESHRE/ASRM-sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril. 2012;97:28-38.e25.
4. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19:41-47.
5. Azziz R, Carmina E, Dewailly D, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009;91:456-488.
6. Mani H, Levy MJ, Davies MJ, et al. Diabetes and cardiovascular events in women with polycystic ovary syndrome: a 20-year retrospective cohort study. Clin Endocrinol (Oxf). 2013;78:926-934.
7. Randeva HS, Tan BK, Weickert MO, et al. Cardiometabolic aspects of the polycystic ovary syndrome. Endocr Rev. 2012;33:812-841.
8. Franks S. The investigation and management of hirsutism. J Fam Plann Reprod Health Care. 2012;38:182-186.
9. Barth JH, Yasmin E, Balen AH. The diagnosis of polycystic ovary syndrome: the criteria are insufficiently robust for clinical research. Clin Endocrinol (Oxf). 2007;67:811-815. (Pubitemid 350135121)
10. Silfen ME, Shackleton CH, Manibo AM, et al. 5α-Reductase and 11β-hydroxysteroid dehydrogenase activity in prepubertal Hispanic girls with premature adrenarche. J Clin Endocrinol Metab. 2002;87:4647-4651. (Pubitemid 35247055)
11. Pardridge WM. Serum bioavailability of sex steroid hormones. Clin Endocrinol Metab. 1986;15:259-278. (Pubitemid 16001796)
12. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999;84:3666-3672. (Pubitemid 30645223)
13. Boots LR, Potter S, Potter D, Azziz R. Measurement of total serum testosterone levels using commercially available kits: high degree of between-kit variability. Fertil Steril. 1998;69:286-292. (Pubitemid 28117108)
14. Loughlin T, Cunningham S, Moore A, Culliton M, Smyth PP, McKenna TJ. Adrenal abnormalities in polycystic ovary syndrome. J Clin Endocrinol Metab. 1986;62:142-147. (Pubitemid 16186856)
15. Stewart PM, Shackleton CH, Beastall GH, Edwards CR. 5 α-Reductase activity in polycystic ovary syndrome. Lancet. 1990;335:431-433. (Pubitemid 20054649)
16. Fassnacht M, Schlenz N, Schneider SB, Wudy SA, Allolio B, Arlt W. Beyond adrenal and ovarian androgen generation: Increased peripheral 5α-reductase activity in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003;88:2760-2766. (Pubitemid 36724453)
17. Ehrmann DA, Barnes RB, Rosenfield RL. Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion. Endocr Rev. 1995;16:322-353.
18. Quinkler M, Sinha B, Tomlinson JW, Bujalska IJ, Stewart PM, Arlt W. Androgen generation in adipose tissue in women with simple obesity - a site-specific role for 17β-hydroxysteroid dehydrogenase type 5. J Endocrinol. 2004;183:331-342. (Pubitemid 39562714)
19. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab. 1998;83:3078-3082. (Pubitemid 28500937)
20. Jones H, Sprung VS, Pugh CJ, et al. Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic pcos phenotypes and healthy controls, independent of obesity and insulin resistance. J Clin Endocrinol Metab. 2012;97:3709-3716.
21. Arlt W, Walker EA, Draper N, et al. Congenital adrenal hyperplasia caused by mutant p450 oxidoreductase and human androgen synthesis: analytical study. Lancet. 2004;363:2128-2135. (Pubitemid 38844154)
22. Yildiz BO, Bolour S, Woods K, Moore A, Azziz R. Visually scoring hirsutism. Hum Reprod Update. 2010;16:51-64.
23. Gregson CL, Paggiosi MA, Crabtree N, et al. Analysis of body composition in individuals with high bone mass reveals a marked increase in fat mass in women but not men. J Clin Endocrinol Metab. 2013;98:818-828.
24. Vassiliadi DA, Barber TM, Hughes BA, et al. Increased 5α-Reductase activity and adrenocortical drive in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2009;94:3558-3566.
25. Cederholm J, Wibell L. Insulin release and peripheral sensitivity at the oral glucose tolerance test. Diabetes Res Clin Pract. 1990;10:167-175. (Pubitemid 20350538)
26. Stumvoll M, Mitrakou A, Pimenta W, et al. Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care. 2000;23:295-301. (Pubitemid 30131733)
27. Kushnir MM, Blamires T, Rockwood AL, et al. Liquid chromatography-tandem mass spectrometry assay for androstenedione, dehydroepiandrosterone, and testosterone with pediatric and adult reference intervals. Clin Chem. 2010;56:1138-1147.
28. Chadwick CA, Owen LJ, Keevil BG. Development of a method for the measurement of dehydroepiandrosterone sulphate by liquid chromatography-tandem mass spectrometry. Ann Clin Biochem. 2005;42:468-474. (Pubitemid 41640519)
29. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81:19-25.
30. Stewart PM, Boulton A, Kumar S, Clark PM, Shackleton CH. Cortisol metabolism in human obesity: impaired cortisone->cortisol conversion in subjects with central adiposity. J Clin Endocrinol Metab. 1999;84:1022-1027. (Pubitemid 29138237)
31. Barber TM, Wass JA, McCarthy MI, Franks S. Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome. Clin Endocrinol (Oxf). 2007;66:513-517. (Pubitemid 46434931)
32. Cakir E, Dogan M, Topaloglu O, et al. Subclinical atherosclerosis and hyperandrogenemia are independent risk factors for increased epicardial fat thickness in patients with PCOS and idiopathic hirsutism. Atherosclerosis. 2013;226:291-295.
33. Dewailly D, Catteau-Jonard S, Reyss AC, Leroy M, Pigny P. Oligoanovulation with polycystic ovaries but not overt hyperandrogenism. J Clin Endocrinol Metab. 2006;91:3922-3927. (Pubitemid 44536865)
34. Gilling-Smith C, Story H, Rogers V, Franks S. Evidence for a primary abnormality of thecal cell steroidogenesis in the polycystic ovary syndrome. Clin Endocrinol (Oxf). 1997;47:93-99. (Pubitemid 27313994)
35. Fruzzetti F, Perini D, Lazzarini V, Parrini D, Gambacciani M, Genazzani AR. Comparison of effects of 3mg drospirenone plus 20 mug ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome. Fertil Steril. 2010;94:1793-1798.
36. Studen KB, Sebestjen M, Pfeifer M, Prezelj J. Influence of spironolactone treatment on endothelial function in non-obese women with polycystic ovary syndrome. Eur J Endocrinol. 2011;164:389-395.
37. Haring R, Hannemann A, John U, et al. Age-specific reference ranges for serum testosterone and androstenedione concentrations in women measured by liquid chromatography-tandem mass spectrometry. J Clin Endocrinol Metab. 2012;97:408-415.
38. Anderson DC. Sex-hormone-binding globulin. Clin Endocrinol (Oxf). 1974;3:69-96.
39. Rosner W, Auchus RJ, Azziz R, Sluss PM, Raff H. Position statement: utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metab. 2007;92:405-413.
40. Cawood ML, Field HP, Ford CG, et al. Testosterone measurement by isotope-dilution liquid chromatography-tandem mass spectrometry: validation of a method for routine clinical practice. Clin Chem. 2005;51:1472-1479. (Pubitemid 41060880)
41. Barber TM, Golding SJ, Alvey C, et al. Global adiposity rather than abnormal regional fat distribution characterizes women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2008;93:999-1004. (Pubitemid 351398585)
42. Barber TM, Franks S. Adipocyte biology in polycystic ovary syndrome. Mol Cell Endocrinol. 2013;373:68-76.
43. Qin K, Ehrmann DA, Cox N, Refetoff S, Rosenfield RL. Identification of a functional polymorphism of the human type 5 17β-hydroxysteroid dehydrogenase gene associated with polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91:270-276. (Pubitemid 43069148)
44. Cara JF, Rosenfield RL. Insulin-like growth factor I and insulin potentiate luteinizing hormone-induced androgen synthesis by rat ovarian thecal-interstitial cells. Endocrinology. 1988;123:733-739.
45. Tosi F, Negri C, Perrone F, et al. Hyperinsulinemia amplifies GnRH agonist stimulated ovarian steroid secretion in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2012;97:1712-1719.
46. Noordam C, Dhir V, McNelis JC, et al. Inactivating PAPSS2 mutations in a patient with premature pubarche. N Engl J Med. 2009;360:2310-2318.
47. Louwers YV, de Jong FH, van Herwaarden NA, et al. Variants in SULT2A1 affect the DHEA sulphate to DHEA ratio in patients with polycystic ovary syndrome but not the hyperandrogenic phenotype. J Clin Endocrinol Metab 2013;98:3848-3855.